We are live on ! Find out more
LAB icon

Standard BioTools

144 hedge funds and large institutions have $480M invested in Standard BioTools in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 39 increasing their positions, 35 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,045% more call options, than puts

Call options by funds: $1.26M | Put options by funds: $110K

11% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 35

3% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 34

1% less funds holding

Funds holding: 145144 (-1)

18.23% less ownership

Funds ownership: 91.46%73.23% (-18%)

33% less capital invested

Capital invested by funds: $719M → $480M (-$239M)

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
144
Holders Change
-1
Holders Change %
-0.69%
% of All Funds
2.08%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
35
Increased
39
Reduced
35
Closed
34
Calls
$1.26M
Puts
$110K
Net Calls
+$1.15M
Net Calls Change
-$1.96M
Name Holding Trade Value Shares
Change
Change in
Stake
TC
176
TwinBeech Capital
New York
-$33.8K -12,480 Closed
WAM
177
Wolverine Asset Management
Illinois
-$271 -100 Closed
AWM
178
Avior Wealth Management
Nebraska
-$84 -31 Closed

LAB Hedge Fund Activity: Q2 2024 in Review

144 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2024, worth a combined $480M — down 33% from $719M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new LAB positions and 34 closed out — a net gain of 1 holder — while 39 added to existing stakes and 35 trimmed.

The largest buyer was BlackRock, adding an estimated $39.8M. The largest seller was Indaba Capital Management, exiting entirely with an estimated $20M sold.

  • 144 institutional investors held Standard BioTools (LAB) as of Q2 2024, down from 145 in Q1 2024.
  • Funds reported $480M of Standard BioTools stock for Q2 2024, down 33% quarter-over-quarter.
  • 35 funds opened new Standard BioTools positions in Q2 2024 and 34 closed out, a net change of +1 holder.
  • The largest Standard BioTools buyer in Q2 2024 was BlackRock, an estimated $39.8M added.
  • The largest Standard BioTools seller in Q2 2024 was Indaba Capital Management, an estimated $20M sold.

Based on aggregated 13F filings for Q2 2024.